Abstract 1147P
Background
MCC is a rare, aggressive cutaneous neoplasm. In September 2017, the European Commission approved avelumab (Ave) for the tx of metastatic MCC based on demonstrated meaningful survival benefit. This study sought to investigate tx patterns and OS of pts with aMCC (stage III/IV) in the National Cancer Registration Dataset (NCRD) in England.
Methods
This cohort included pts ≥18 years and newly diagnosed with stage III/IV MCC (ICD-O: C44, 8247 morphology) between January 2013 and December 2020 in the NCRD in England and followed up until May 2022. Summary and descriptive statistics were calculated for categorical and continuous variables. The Kaplan-Meier method was used to estimate median OS from diagnosis date (overall) and OS from initiation of 1L tx stratified by regimens received and by stage at baseline.
Results
A total of 667 pts with aMCC were included. Mean age (SD) was 77.4 years (10.3), most pts were male (61.0%), and 14.1% were immunocompromised. At diagnosis, 66.3% and 33.7% had stage III and IV disease, respectively. The mean (SD) baseline modified Deyo-Charlson Comorbidity Index was 4.0 (1.8). Overall, 478 pts (71.7%) died during follow-up; median OS from diagnosis was 18.4 months (95% CI, 15.6-20.9). In total, 199 pts (29.8%) received 1L tx (39.2% Ave, 60.8% non-Ave). When stratified by stage, 26.9% of stage III pts received systemic tx (39.5% Ave, 60.5% non-Ave); the corresponding numbers for stage IV pts were 35.6% (38.7% Ave, 61.3% non-Ave). OS from 1L initiation is presented in the table. Table: 1147P
OS from 1L initiation | Stage III | Stage IV | ||
Ave | Non-Ave | Ave | Non-Ave | |
n | 47 | 72 | 31 | 49 |
Deaths during follow-up, n (%) | 20 (42.6) | 54 (75.0) | 16 (51.6) | 40 (81.6) |
Median OS months (95% CI) | 37.8 (12.9-NE) | 13.0 (8.3-19.6) | 19.9 (5.0-NE) | 7.2 (5.9-9.1) |
12-months survival rate, % (95% CI) | 67 (51-79) | 52 (40-63) | 55 (36-70) | 31 (18-44) |
18-months survival rate, % (95% CI) | 56 (39-69) | 41 (29-52) | 52 (33-67) | 24 (14-37) |
24-months survival rate, % (95% CI) | 56 (39-69) | 35 (24-46) | 48 (29-64) | NE |
NE, not estimable.*Non-Ave includes 95.5% chemotherapy and 4.5% other treatment.
Conclusions
This nationwide real-world study of pts with aMCC demonstrates the effectiveness of Ave with considerably prolonged survival in pts with both stage III and stage IV disease. The study findings validate results from the JAVELIN Merkel 200 clinical trial and other observational studies.
Clinical trial identification
Editorial acknowledgement
Editorial support was provided by Eleanor Bishop on behalf of Clinical Thinking and was funded by Merck and Pfizer.
Legal entity responsible for the study
The authors.
Funding
This study was sponsored by Merck (CrossRef Funder ID: 10.13039/100009945), as part of an alliance between Merck and Pfizer.
Disclosure
C. Knott: Financial Interests, Personal, Full or part-time Employment: Health Data Insight CIC; NHS England. S. Mahmoudpour, M. Kearney: Financial Interests, Personal, Full or part-time Employment: Merck. E. Boutmy: Financial Interests, Personal, Full or part-time Employment: Merck; Financial Interests, Personal, Stocks/Shares: Merck. P. Verpillat: Financial Interests, Personal, Full or part-time Employment, at the time of the study: Merck.
Resources from the same session
1109P - Second-line pembrolizumab (pembro) in Chinese patients (pts) with advanced melanoma: Long-term follow-up of the phase I KEYNOTE-151 study
Presenter: Lu Si
Session: Poster session 13
1110P - A phase II clinical trial of SHR-1701 combined with temozolomide for advanced melanoma
Presenter: Tu Hu
Session: Poster session 13
1111P - A randomised phase II study of intermittent versus continuous dosing of targeted therapy in patients with BRAFV600 mutant advanced melanoma (INTERIM)
Presenter: Avinash Gupta
Session: Poster session 13
1112P - Five-year survival after intermittent targeted therapy and anti-PD1 in stage IV melanoma: An update of the IMPemBra trial
Presenter: Lotte Hoeijmakers
Session: Poster session 13
1113P - COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (enco) + binimetinib (bini) vs vemurafenib (vemu) or enco in patients (pts) with BRAF V600–mutant melanoma
Presenter: Dirk Schadendorf
Session: Poster session 13
1114P - Encorafenib (E) plus binimetinib (B) in unresectable advanced or metastatic BRAFV600-mut melanoma, real-world evidence in Spain (GEM 2002 - BECARE)
Presenter: Ainara Soria Rivas
Session: Poster session 13
1115P - Comparison of efficacy and toxicity of dabrafenib/trametinib versus vemurafenib/cobimetinib therapy in routine medical practice: Eight years of BRAF/MEK inhibitor use in routine clinical practice
Presenter: Karolina Piejko
Session: Poster session 13
1116P - Long term outcome of complete responders to immune checkpoint inhibitors (ICI) or target therapy (TT) in advanced melanoma
Presenter: Celine Boutros
Session: Poster session 13
1117P - Overall survival (OS) in patients with metastatic BRAF V600-mutant melanoma treated with encorafenib plus binimetinib (ENCO+BINI): Comparing real-world vs clinical trial data
Presenter: Gino In
Session: Poster session 13
1118P - Real-world treatment patterns and outcomes among patients with BRAF+ metastatic melanoma refractory to first-line immunotherapy
Presenter: Thach-Giao Truong
Session: Poster session 13